Gilead Sciences will announce data from several ongoing trials in human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) at the upcoming 25th International AIDS Conference 2024.
The company, considered one of the global leaders in HIV and AIDS research, will present data from three trials at the conference, taking place in Munich, Germany, between 22 and 26 July.
Go deeper with GlobalData
Virology Clinical Development senior vice president Dr Jared Baeten said: “The AIDS 2024 conference convenes the global HIV community – scientists, advocates, and partners from the public and private sectors.
“Our contributions to this year’s meeting demonstrate Gilead’s leadership in person-centred innovations across HIV prevention, treatment, and cure. Our scientific advancements are grounded in collaboration with community and research partners around the world. I look to a future where every person has options to help obtain their own HIV prevention or treatment success and where we’ve come together to end the HIV epidemic.”
The company will announce full data from the Phase III, pivotal PURPOSE 1 trial (NCT04994509) evaluating lenacapavir and emtricitabine/tenofovir alafenamide in adolescent girls and young women at risk of HIV.
In June, the topline results demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women from the pre-exposure prophylaxis (PrEP) treatment in the first prevention trial intentionally for pregnant and lactating women.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGilead will also present 48-week data from the Phase II/III ARTISTRY-1 (NCT05502341) trial investigating once-daily bictegravir and lenacapavir in virologically suppressed people with HIV who are on a complex regimen.
Finally, the company will present two-year outcomes from BICSTaR trial (NCT03580668), an ongoing global, observational study evaluating the effectiveness, safety and tolerability of Biktarvy (bictegravir 50mg / emtricitabine 200mg / tenofovir alafenamide 25mg tablets, B/F/TAF) in treatment-naïve and treatment-experienced people with HIV who have a high burden of co-morbidities.
The company will also look at data from pipeline candidates GS-1720 (NCT05585307) and GS-4182, which are being evaluated in Phase I trials.
HIV landscape
The HIV landscape is constantly evolving, with ongoing efforts to combat the disease through clinical trials, research, and the development of new treatments.
Currently, antiretroviral therapy (ART) is the primary treatment for HIV-positive patients. It is a daily treatment method that works by reducing the replication of the virus in the blood, resulting in undetectable and non-transmissible viral levels.
Despite the high availability of ART, there are still barriers to accessing treatment. Approximately 27% of those infected with HIV do not have access to antiretroviral therapies. ART therapies can also have substantial side effects and are expensive.
